Janux 治療公司
US ˙ NasdaqGM ˙ US47103J1051

SecurityJANX / Janux Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership703,940 shares
Latest Disclosed Value $ 9,784,767
Morgan Stanley reports 13.84% increase in ownership of JANX / Janux Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 703,940 shares of Janux Therapeutics, Inc. (US:JANX) valued at $9,784,766 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 618,385 shares of Janux Therapeutics, Inc.. This represents a change in shares of 13.84% during the quarter. The current value of the position is $9,686,214 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F JANUX THERAPEUTICS COM 47103J105 703,940 85,555 13.84 9,785 14.66 0.0006
2026-05-27 2025-12-31 13F/A-1 JANUX THERAPEUTICS COM 47103J105 618,385 122,750 24.77 8,534 -29.56 0.0005
2026-02-13 2025-12-31 13F JANUX THERAPEUTICS COM 47103J105 618,385 122,750 8,534 0.0005
2026-05-27 2025-09-30 13F/A-1 JANUX THERAPEUTICS COM 47103J105 495,635 179,904 56.98 12,113 66.09 0.0007
2025-11-14 2025-09-30 13F JANUX THERAPEUTICS COM 47103J105 495,635 179,904 12,113 0.0007
2025-08-15 2025-06-30 13F JANUX THERAPEUTICS COM 47103J105 315,731 33,304 11.79 7,293 -4.35 0.0005
2025-05-15 2025-03-31 13F JANUX THERAPEUTICS COM 47103J105 282,427 64,596 29.65 7,626 -34.62 0.0005
2025-05-15 2024-12-31 13F/A-1 JANUX THERAPEUTICS COM 47103J105 217,831 77,367 55.08 11,663 82.76 0.0008
2025-02-14 2024-12-31 13F JANUX THERAPEUTICS COM 47103J105 217,831 77,367 11,663 0.0008
2025-05-14 2024-09-30 13F/A-2 JANUX THERAPEUTICS COM 47103J105 140,464 58,666 71.72 6,381 86.25 0.0005
2025-02-14 2024-09-30 13F/A-1 JANUX THERAPEUTICS COM 47103J105 140,464 58,666 6,381 0.0005
2024-11-14 2024-09-30 13F JANUX THERAPEUTICS COM 47103J105 140,464 58,666 6,381 0.0001
2025-05-14 2024-06-30 13F/A-2 JANUX THERAPEUTICS COM 47103J105 81,798 -39,433 -32.53 3,427 -24.93 0.0003
2024-10-17 2024-06-30 13F/A-1 JANUX THERAPEUTICS COM 47103J105 81,798 -39,433 3,427 0.0003
2024-08-14 2024-06-30 13F JANUX THERAPEUTICS COM 47103J105 81,798 -39,433 3,427 0.0003
2024-10-17 2024-03-31 13F/A-2 JANUX THERAPEUTICS COM 47103J105 121,231 53,783 79.74 4,564 531.26 0.0004
2024-08-16 2024-03-31 13F/A-1 JANUX THERAPEUTICS COM 47103J105 121,231 53,783 4,564 0.0000
2024-05-15 2024-03-31 13F JANUX THERAPEUTICS COM 47103J105 121,231 53,783 4,564 0.0004
2024-08-16 2023-12-31 13F/A-1 JANUX THERAPEUTICS COM 47103J105 67,448 46,992 229.72 724 250.97 0.0001
2024-02-13 2023-12-31 13F JANUX THERAPEUTICS COM 47103J105 67,448 46,992 724 0.0001
2023-11-15 2023-09-30 13F JANUX THERAPEUTICS COM 47103J105 20,456 1,975 10.69 206 -5.94 0.0000
2023-08-14 2023-06-30 13F JANUX THERAPEUTICS COM 47103J105 18,481 -15,023 -44.84 219 -45.93 0.0000
2023-05-15 2023-03-31 13F JANUX THERAPEUTICS COM 47103J105 33,504 16,020 91.63 405 76.09 0.0000
2023-02-14 2022-12-31 13F JANUX THERAPEUTICS COM 47103J105 17,484 -123,996 -87.64 230 -88.00 0.0000
2022-11-14 2022-09-30 13F JANUX THERAPEUTICS COM 47103J105 141,480 113,747 410.15 1,916 468.55 0.0003
2022-10-27 2022-06-30 13F/A-1 JANUX THERAPEUTICS COM 47103J105 27,733 -10 -0.04 337 -15.33 0.0000
2022-08-15 2022-06-30 13F JANUX THERAPEUTICS COM 47103J105 27,733 -10 337 0.0000
2022-10-27 2022-03-31 13F/A-1 JANUX THERAPEUTICS COM 47103J105 27,743 13,264 91.61 398 39.65 0.0001
2022-05-13 2022-03-31 13F JANUX THERAPEUTICS COM 47103J105 27,743 13,264 398 0.0001
2022-02-14 2021-12-31 13F JANUX THERAPEUTICS COM 47103J105 14,479 7,777 116.04 285 96.55 0.0000
2021-11-15 2021-09-30 13F JANUX THERAPEUTICS COM 47103J105 6,702 6,602 6,602.00 145 7,150.00 0.0000
2021-08-23 2021-06-30 13F/A-1 JANUX THERAPEUTICS COM 47103J105 100 100 2 0.0000
2021-08-16 2021-06-30 13F JANUX THERAPEUTICS COM 47103J105 100 100 2 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.